Science

Publications

Jun 23, 2017
Luspatercept
Luspatercept Increases Hemoglobin and Decreases Transfusion Burden in Adults With Beta-Thalassemia. European Hematology Association Congress. .
View Publication
Jun 23, 2017
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Long-Term Results From the Phase 2 PACE-MDS Study. European Hematology Association Congress. .
View Publication
May 6, 2017
Luspatercept
Luspatercept Response in New Subpopulations of Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Update of the PACE Study. MDS Symposium 2017. .
View Publication
Dec 5, 2016
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study. ASH 2016. .
View Publication
Dec 5, 2016
Luspatercept
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden, and Improves Patient-Reported Outcomes in Adults with Beta-Thalassemia. ASH 2016. .
View Publication
Dec 4, 2016
Luspatercept
Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Beta-Thalassemia: Preliminary Results From Phase 2 Studies. .
View Publication
Dec 4, 2016
Luspatercept
Pharmacokinetics and Exposure–Response of Luspatercept in Patients With Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results From Phase 2 Studies. ASH 2016. .
View Publication
Dec 1, 2016
Dalantercept
A Phase 2 Study of Dalantercept, an Activin Receptor-Like Kinase-1 Ligand Trap, in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Cancer, a journal of the American Cancer Society. vol. 122 no. 23, .
View Publication
Nov 10, 2016
ACE-083
A Phase 2 study to evaluate ACE-083, a local muscle therapeutic, in patients with FSHD. FSH Society 2016 Research Connect Conference. .
View Publication
Oct 6, 2016
ACE-083
A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. Patient-Centered Charcot-Marie-Tooth Summit. .
View Publication
Sep 9, 2016
ACE-083
A Phase 1 Healthy Volunteer Study of ACE-083, a Novel, Locally-Acting Muscle Agent. 6th International CMTR Consortium Meeting. .
View Publication
Jul 8, 2016
ACE-083
ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases. .
View Publication
Jun 12, 2016
Luspatercept
Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association. .
View Publication
Jun 11, 2016
Luspatercept
Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with Beta-Thalassemia. Congress of the European Hematology Association. .
View Publication
Jun 10, 2016
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low- Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE‐MDS Study. 21st Congress of the European Hematology Association. .
View Publication
Jun 10, 2016
Luspatercept
RAP-536 (Murine Analog of ACE-536/Luspatercept) Inhibits SMAD2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in a Murine Model of Beta-Thalassemia. 21st Congress of the European Hematology Association. .
View Publication
Apr 2, 2016
ACE-083
ACE-083, a Locally-Acting TGF-Beta Superfamily Ligand Trap, Increases Muscle Volume of Targeted Muscle: Preliminary Results from a Phase 1 Dose Escalation Study in Healthy Volunteers. ENDO 2016. .
View Publication
Mar 21, 2016
ACE-083
ACE-083, a locally-acting TGF-beta superfamily ligand trap, increases muscle volume of targeted muscle: Preliminary results from a Phase 1 dose escalation study in healthy volunteers. 2016 MDA Clinical Conference. .
View Publication
Mar 21, 2016
ACE-083
ACE-083, a Locally-Acting TGF-β Superfamily Ligand Trap, Increases Muscle Mass and Strength in a Mouse Model of ALS. 2016 MDA Clinical Conference. .
View Publication
Dec 10, 2015
ACE-083
Phase 1 dose escalation study of ACE-083 in healthy volunteers: Preliminary results for a locally acting muscle therapeutic. The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) Conference. .
View Publication View Additional Publication Info
Dec 7, 2015
Sotatercept
Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
ACE-1332
TGFβ1 Antagonist Inhibits Fibrosis in a Murine Model of Myelofibrosis. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
Luspatercept
RAP-536 (Murine ACE-536/Luspatercept) Inhibits Smad2/3 Signaling and Promotes Erythroid Differentiation by Restoring GATA-1 Function in Murine β-Thalassemia. The 57th Annual American Society of Hematology. .
View Publication
Dec 7, 2015
Luspatercept
Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study. The 57th Annual American Society of Hematology. .
View Publication
Dec 6, 2015
Luspatercept
Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study. The 57th Annual American Society of Hematology. .
View Publication
Dec 5, 2015
Luspatercept
Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study. The 57th Annual American Society of Hematology. .
View Publication
Nov 6, 2015
Dalantercept
The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. .
View Publication
Nov 6, 2015
Dalantercept
The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. .
View Publication
Nov 6, 2015
Sotatercept
Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Subjects: Interim Analysis of a Phase 2 Study. The 48th Annual American Society of Nephrology Kidney Week. .
View Publication
Nov 5, 2015
Sotatercept
Sotatercept Improves Anemia, Vascular Calcification, and Bone Loss in Patients With End-Stage Kidney Disease on Hemodialysis. American Society of Nephrology Kidney Week 2015. .
View Publication
Oct 5, 2015
ACE-083
Poster Presentation – A phase 1 dose escalation study of ACE-083, a locally-acting muscle therapeutic, in healthy volunteers. FSHD International Research Consortium. .
View Publication
Oct 1, 2015
ACE-2494
ACE-2494, a Novel GDF Ligand Trap, Increases Muscle Mass Upon Systemic Administration in Mice. 20th International Congress of the World Muscle Society. .
View Publication
Oct 1, 2015
ACE-083
ACE-083 Increases Muscle Hypertrophy and Strength in C57BL/6 Mice. 20th International Congress of the World Muscle Society. .
View Publication
Sep 14, 2015
Sotatercept
Sotatercept (ACE-011) for the Treatment of Chemotherapy-Induced Anemia in Patients with Metastatic Breast Cancer or Advanced or Metastatic Solid Tumors Treated with Platinum-Based Chemotherapeutic Regimens: Results from Two Phase 2 Studies. Supportive Care in Cancer 2015. .
View Publication
Jun 13, 2015
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk MDS: Preliminary Results from the Phase 2 PACE-MDS Study. 20th Congress of the European Hematology Association. .
View Publication
Jun 12, 2015
Luspatercept
Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Liver Iron Concentration in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 20th Congress of the European Hematology Association. .
View Publication
Jun 5, 2015
Dalantercept
Endothelial ALK1 is a Therapeutic Target for Impairing Metastatic Dissemination of Breast Cancer. Cancer Research. vol. 7 no. 12, .
View Publication
Jun 1, 2015
Dalantercept
Poster – The DART Study: Dalantercept Part 1. American Society of Clinical Oncology (ASCO) Annual Meeting. .
View Publication
Jun 1, 2015
Dalantercept
Poster – The DART Study: Dalantercept Part 2. American Society of Clinical Oncology (ASCO) Annual Meeting. .
View Publication
May 30, 2015
Sotatercept
Quantitative Computed Tomography Results for Bone Mass and Abdominal Aortic Vascular Calcification in Hemodialysis Subjects Treated With Escalating Dose Levels of Sotatercept: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress. .
View Publication
May 29, 2015
Sotatercept
The Role of Activin Signaling in the Pathogenesis of Renal Osteodystrophy of CKD-MBD. 52nd ERA-EDTA Congress. .
View Publication
May 29, 2015
Sotatercept
Sotatercept May 29, 2015 Long-term Effects of 3 Dose Levels of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001. 52nd ERA-EDTA Congress. .
View Publication
May 2, 2015
Luspatercept
Oral Presentation: Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study. 13th International Symposium on Myelodysplastic Syndromes (MDS). .
View Publication
Apr 29, 2015
Sotatercept
Oral Presentation – A Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. 13th International Symposium on Myelodysplastic Syndromes (MDS). .
View Publication
Feb 28, 2015
Dalantercept
Poster – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. .
View Publication
Feb 28, 2015
Dalantercept
Oral Presentation – The DART Study: Part 1 results of dose escalation and expansion cohorts of dalantercept plus axitinib in advanced renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium. .
View Publication
Jan 16, 2015
Dalantercept
The DASH STUDY: A Phase 1b Study of Dalantercept Plus Sorafenib in Advanced Hepatocelluar Carcinoma. American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium. .
View Publication
Dec 8, 2014
Luspatercept
Modified ActRIIB-mFc Fusion Protein Mitigates Sickling and Red Cell Pathology in a Murine Model of Sickle Cell Disease. 56th Annual American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 8, 2014
Luspatercept
Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results from a Phase 2 Study. 56th Annual American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 7, 2014
Sotatercept
An Open-Label, Phase 2, Dose-Finding Study of Sotatercept in Patients With Low- or Intermediate-1-Risk Myelodysplastic Syndromes or Non-Proliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion. 56th American Society of Hematology Annual Meeting and Exposition. .
View Publication
Dec 7, 2014
Luspatercept
Luspatercept Increases Hemoglobin and Decreases Transfusion Burden and Serum Ferritin in Adults with Beta-Thalassemia: Preliminary Results from a Phase 2 Study. 56th American Society of Hematology Annual Meeting and Exposition. .
View Publication
Nov 13, 2014
Sotatercept
Sotatercept: Results for Bone Mass and Vascular Calcification in Hemodialysis Subjects Treated With Escalating Doses: Interim Analysis of ACE-011-REN-001. American Society of Nephrology Kidney Week 2014. .
View Publication
Nov 13, 2014
Sotatercept
Safety and Hemoglobin Effect of the First 28-Day Dose Cycle of Sotatercept 0.7 mg/kg Compared With Lower Doses and Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis. American Society of Nephrology Kidney Week 2014. .
View Publication
Oct 9, 2014
ACE-083
ACE-083, a Ligand Trap for Members of the TGF-β Superfamily, Increases Muscle Mass Locally in a Mouse Model of Duchenne Muscular Dystrophy. 19th International Congress of the World Muscle Society. .
View Publication
Jul 1, 2014
ACE-083
A Modified Cysteine Knot Ligand Trap of the TGF-β Superfamily, ACE-083, Increases Muscle Mass Locally in Mice. 13th International Congress on Neuromuscular Diseases. .
View Publication
Jun 19, 2014
Luspatercept
Modified Activin Receptor IIB Ligand Trap Mitigates Ineffective Erythropoiesis and Disease Complications in Murine Beta-Thalassemia. Blood 2014. vol. 123 no. 25, .
View Publication
Jun 14, 2014
Luspatercept
Modified ActRIIB-Fc Fusion Protein (ACE-536) Decreases Irreversible Sickle Cells in a Murine Model of Sickle Cell Disease. European Hematology Associtation 19th Congress. .
View Publication
Jun 1, 2014
Sotatercept
Long-term Effects of Sotatercept Compared With Placebo for Correction of Anemia in Hemodialysis Subjects: Interim Analysis of ACE-011-REN-001 Phase 2A Study. 51st ERA-EDTA Congress. .
View Publication
May 30, 2014
Dalantercept
A Phase 2 Randomized Study of Dalantercept Plus Axitinib Versus Placebo Plus Axitinib in Advanced Renal Cell Carcinoma: Results from the Part 1 Dose Escalation and Expansion Cohorts. American Society of Oncology Annual Meeting. .
View Publication
May 30, 2014
Dalantercept
Phase 2 Study of Dalantercept Monotherapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Society of Oncology Annual Meeting. .
View Publication
Apr 26, 2014
Luspatercept
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers. Am. J. Hematol. .
View Publication
Apr 23, 2014
Sotatercept
Interim Analysis of ACE-011-REN-001: The First 28 Day Dose Cycle of Low and Medium Starting Doses of Sotatercept Compared to Placebo for Correction of Anemia in Hemodialysis Subjects. Poster #81. National Kidney Foundation (NKF) 2014 Spring Clinical Meeting . .
View Publication
Apr 17, 2014
Luspatercept
Targeting a New Regulator of Erythropoiesis to Alleviate Anemia. Nature Medicine. vol. 20 no. 4, .
Apr 8, 2014
Dalantercept
Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?. Clinical Cancer Research 2014. .
View Publication
Mar 25, 2014
Sotatercept
An Activin IIa Ligand Trap Corrects Ineffective Erythropoiesis in β-Thalassemia. Nature Medicine 2014. .
View Publication
Mar 25, 2014
Luspatercept
Transforming Growth Factor-β Superfamily Ligand Trap ACE-536 Corrects Anemia by Promoting Late-Stage Erythropoiesis. Nature Medicine 2014. .
View Publication
Mar 21, 2014
Sotatercept
Sotatercept in Patients with Osteolytic Lesions of Multiple Myeloma. British Journal of Haematology 2014. .
View Publication
Mar 18, 2014
Sotatercept
An Activin Receptor IIA Ligand Trap Promotes Erythropoiesis Resulting in a Rapid Induction of Red Blood Cells and Haemoglobin. British Journal of Haematology 2014. .
View Publication
Jan 15, 2014
Dalantercept
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor-like Kinase 1 Ligand Trap, in Patients with Advanced Cancer. Clin Cancer Research 2014. vol. 20,
View Publication
Dec 9, 2013
Sotatercept
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results. Blood 2013. vol. 122,
View Publication
Aug 16, 2013
Sotatercept
Multiple-Dose, Safety, Pharmacokinetic, Pharmacodynamic Study of Sotatercept, a Novel Erythropoietic Agent, in Healthy Postmenopausal Women. J Clin Pharmacol. vol. 53 no. 11, .
View Publication
Jan 28, 2013
ACE-031
A Single Ascending-Dose Study of Muscle Regulator ACE-031 in Healthy Volunteers. Muscle & Nerve. vol. 47, .
Nov 6, 2012
Sotatercept
Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opinion on Investigational Drugs. vol. 22 no. 1,
View Publication
Jul 3, 2012
ACE-661
A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. PNAS 2012. vol. 109 no. 30,
View Publication
Jun 30, 2011
Dalantercept
ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011. vol. 117 no. 26,
View Publication
May 1, 2011
ACE-031
Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle & Nerve 2011. vol. 4 no. 5,
View Publication
Mar 1, 2011
ACE-031
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol 2011. vol. 178 no. 3,
View Publication
Dec 1, 2010
Sotatercept
Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J. Bone Miner Res 2010. vol. 25 no. 12, .
View Publication
Oct 1, 2010
Sotatercept
Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010. vol. 12 no. 5, .
View Publication
Sep 1, 2010
ACE-031
A Soluble Activin Receptor Type IIB Prevents the Effects of Androgen Deprivation on Body Composition and Bone Health. Endocrinology 2010. vol. 151 no. 9, .
View Publication
Jul 2, 2010
ACE-031
Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB. J Biol Chem. vol. 285 no. 27, .
View Publication
May 13, 2010
ACE-031
Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type. J Appl Physiol . vol. 109 no. 3, .
View Publication
Apr 1, 2010
Sotatercept
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010. vol. 46 no. 4,
View Publication
Mar 16, 2010
Sotatercept
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. PNAS 2010. vol. 107 no. 11,
View Publication
Feb 2, 2010
Dalantercept
ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Mol Cancer Ther 2010. vol. 9 no. 2,
View Publication
Jan 1, 2010
Dalantercept
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010. vol. 207 no. 1,
View Publication
Jan 1, 2010
Sotatercept
Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone 2010. vol. 46 no. 1,
View Publication
Nov 1, 2009
ACE-031
The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond). vol. 33 no. 11,
View Publication
Oct 28, 2009
ACE-031
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol. vol. 298,
View Publication
Dec 1, 2008
Sotatercept
Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women. J Bone Min Res 2009. vol. 24 no. 4,
View Publication
May 13, 2008
Sotatercept
A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. PNAS 2008. vol. 105 no. 19,
View Publication